Stockholm Stock Exchange | Mid Cap
Bioarctic
+44.59%
Latest
+29.90%
3 months
DNBCarnegieNordea MarketsRBCRX SecuritiesDNB Markets

Price Targets For Bioarctic

AnalystPrice TargetDateUpside
DNB430 SEKJan 9
+44.59%
Carnegie373 SEKJan 9
Nordea Markets356 SEKNov -22
RBC460 SEKSep -22
RX Securities205 SEKApr -22
DNB Markets250 SEKJul -21

About The Company

BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression.
Bioarctic